In The News: School of Integrated Health Sciences

MedPageToday

Two new assessments of clinical trials pointed to the need for more investment in Alzheimer's disease treatments. At the 2024 American Geriatrics Societyopens in a new tab or window (AGS) scientific meeting, researchers evaluated Alzheimer's trials funded by the National Institute on Aging (NIA) over a 20-year period. Another analysis, published in Alzheimer's and Dementia: Translational Research and Clinical Interventionsopens in a new tab or window, provided a comprehensive look at active trials in the Alzheimer's drug pipeline.

Newswise

Mice experiencing “social jet lag” developed characteristics similar to people with the same phenomenon, including significant weight gain, higher blood sugar levels and lower cardiovascular fitness. Results of the study by researchers at the University of Nevada, Las Vegas are published in the Journal of Applied Physiology. It has been chosen as an APSselect article for May.

GQ

In many ways, alcohol and sports go hand-in-hand: Marathon winners celebrate with an ice-cold drink at the finish line, pro teams partner with booze brands, and “beer league” amateur sports often live up to their name. But a shift may be underway, as a growing number of Americans are drinking less for health reasons, on the heels of a new wave of research about the impacts of even moderate drinking. In 2023, the World Health Organization contradicted a long-held belief: No, moderate alcohol consumption, like a glass of red wine at dinner, won’t increase your lifespan. Actually, any amount is actively bad for you.

Woman's World

Let’s face it: Between busy schedules, tempting treats and the allure of convenience foods, sticking to a healthy diet can be a challenge. Thankfully, healthy eating hacks can help you reach your wellness goals without feeling deprived. We asked experts to break down what tricks actually work, plus how to effortlessly incorporate them into your daily life.

Time

I’ve spent my whole life happily walking in one direction: forward. It was, I believed, the only way to go, so I dutifully logged dozens of miles a month looking like every other person out for a morning stroll.

KSNV-TV: News 3

People with Down syndrome experience physical difficulties that can make it more challenging to live an active lifestyle. Researchers at the University of Nevada, Las Vegas CArdiovascular Research and Exercise Lab (CARE Lab) are attempting to assess how a lower heart rate, a feature of Down syndrome, can impact people’s ability to move and exercise.

Mirage News

The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.

Science Mag

The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.

European Pharmaceutical Review

Considering current developments in Alzheimer’s drugs, a US expert has predicted that the industry should “be prepared for more complex biological therapies that require intravenous infusion and vigilant monitoring for side effects; more like cancer therapies,” according to Dr Jeffrey Cummings, Alzheimer’s clinician-scientist and research professor at the School of Integrated Health Sciences, University of Nevada, Las Vegas.

Newswise

The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.

Medical Xpress

The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. On the heels of newly FDA-approved drugs Aduhelm (aducanumab) in 2021 and Leqembi (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.

The News International

A recent study published in Scientific Reports has found that strength training two to three times per week can be used as an effective treatment for arterial hypertension commonly known as high blood pressure. The researchers from School of Technology and Sciences Sao Paulo State University UNESP in Brazil looked at data from 14 studies featuring 253 participants.